Fig. 4
From: Pharmacologic inhibition of IL11/STAT3 signaling increases MHC-I expression and T cell infiltration
STAT3 exerts key role in IL11 inhibition of chemokine and MHC I molecule expression. A, B Immunoblot of STAT1/3 (total and phosphorylated) in IL11-treated (100 ng/ml) STAT3-knockdown MC38 with/without IFNγ induction (10 ng/ml). STAT1 phosphorylation ratio was calculated. Data presented as means ± SD from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, t test. C mRNA expression of CXCL9, H2-D1, H2-K1 in IL11-treated (100/200 ng/ml) STAT3-knockdown MC38 with/without IFNγ induction (10 ng/ml). Data presented as fold change to control group and means ± SEM from three independent experiments. **P < 0.01, ***P < 0.001, t test. D Representative images of STAT3-knockdown MC38 subcutaneous tumors in Il11−/− mice with/without recombinant IL11 (reIL11, 10 mg/kg B.W.; n = 6 mice/group). E Tumor volume (cm3) of STAT3-knockdown MC38 subcutaneous tumors in Il11−/− mice with/without reIL11 (10 mg/kg B.W., n = 6 mice/group). ***P < 0.001, two-way ANOVA. F Tumor weight of MC38 subcutaneous tumors in WT and Il11−/− mice (n = 6 mice/group). ***P < 0.001, t test. G, H Immunofluorescence and cell counts of CD8 (yellow) and DAPI (blue) of STAT3-knockdown MC38 subcutaneous tumors in Il11−/− mice with/without reIL11 (10 mg/kg B.W., n = 6 mice/group). Scale bar, 50 μm. ***P < 0.001, t test. I, J Immunoblot of STAT1/3 (total and phosphorylated) in IL11-treated (100 ng/ml) Stat3fl/fl + Adeno-GFP/Adeno-Cre organoids with/without IFNγ induction (10 ng/ml). STAT1 phosphorylation ratio was calculated. Data presented as means ± SD from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, t test. K mRNA expression of CXCL9, H2-D1, H2-K1 in IL11-treated (100/200 ng/ml) Stat3fl/fl + Adeno-GFP/Adeno-Cre organoids with/without IFNγ induction (10 ng/ml). Data presented as fold change to control group and means ± SEM from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, t test